Our History
We are a Polish pharmaceutical company with almost 100 years of tradition, and constantly looking for new ways of development.
Many years of experience and achievements of the company are the best proof of our commitment, the beneficiaries of which are our business partners and patients themselves.
See how we have changed over the years!
1944
Opening of the Typhoid Vaccine Production Laboratory and the Serum and Vaccine Production Plant at the NIH Branch in Lublin.
Production begins, including vaccines against:
- rabies,
- dysentery,
- typhoid fever,
and the sera:
- anti-diphtheria
- anti-tetanus.
1951
The Department is separated from the structures of the National Institute of Hygiene and since then we have been operating as the Lublin Serum and Vaccine Factory.
1959
Two more breakthrough drugs for health protection are developed - the production of the polio vaccine (the virus that causes Heine-Medina disease) is launched and we start the production of the Lakcid® bacterial preparation.
1960
The Lublin Production Plant of Serums and Vaccines changes its name. Since then, we have been operating as the Serum and Vaccine Factory in Lublin.
1966
We are constantly working on improving our medicines. This year, Lakcid has been enriched with 3 more mutants, thus gaining resistance to neomycin, erythromycin and tetracycline.
1967
We register and start the production of Distreptaza, another important drug constituting a breakthrough therapy, this time in the field of gynecology and proctology.
1973
The production plant introduces the most modern production technology that allows to obtain 100% sterility in the preparation of bacterial suspensions for the production of probiotics.
1985-1988
The Lublin Factory introduces new technologies to improve serial production, and also starts research work together with the Central Laboratory of Vaccines and Serums in Warsaw on antibiotic resistance.
1988-1990
The right technology is finally developed and a new medicinal preparation named Lakcid Forte is produced, containing four times more Lactobacillus rhamnosus than Lakcid.
1994
The plant celebrates the 50th anniversary of the establishment of the plant. Our most important products are:
- tuberculosis vaccine,
- Lakcid,
- Biogonadil,
- Thrombin,
- Gastrothrombin,
- Histaglobin.
1999
After several years of efforts, the privatization process is completed. An employee-owned company called "Biomed", a Serum and Vaccine Factory LLC in Lublin, is established.
2001
Research work with the Department of Microbiology at the Jagiellonian University Medical College in Krakow resulted in a breakthrough increase in the resistance of Biomed's probiotics to as many as 27 groups of antibiotics.
2004
Introduction to the market of a new probiotic medicinal product Lakcid L.
2010- 2011
In 2010, the legal form of the enterprise was changed to a joint-stock company. A year later, on July 9, Biomed-Lublin enters the alternative market of the Warsaw Stock Exchange - NewConnect.
In the same year, the Main Pharmaceutical Inspectorate grants Biomed a GMP certificate in the field of manufacturing processes.
2012-2014
We register other extremely important plasma-like products: albumin, human coagulation factor VIII, and human normal immunoglobulin for intravenous administration.
2015
The company's debut on the Warsaw Stock Exchange. On January 30, BIOMED-LUBLIN issues its first shares on the main market.
2019-2020
We are starting a new, groundbreaking investment in the development of our own Research and Development Center (CBR), co-financed by PARP.
2021
We are launching another extremely important investment - the construction of a commercial line for the production of Onko BCG, an innovative drug against bladder cancer, which is an alternative and supplement to chemotherapy.
2023
The company focuses on development and creates a new strategy, which is accompanied by rebranding. Since then it has been known as the Synthaverse.
